These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 30242498)

  • 1. Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman's age and markers of ovarian reserve.
    Di Paola R; Garzon S; Giuliani S; Laganà AS; Noventa M; Parissone F; Zorzi C; Raffaelli R; Ghezzi F; Franchi M; Zaffagnini S
    Arch Gynecol Obstet; 2018 Nov; 298(5):1029-1035. PubMed ID: 30242498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study.
    Papaleo E; Zaffagnini S; Munaretto M; Vanni VS; Rebonato G; Grisendi V; Di Paola R; La Marca A
    Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():94-99. PubMed ID: 27835829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram to predict FSH starting dose in poor ovarian response women in progestin primed ovarian stimulation protocol.
    Wu S; Li Y; Wu G; Wu H
    BMC Womens Health; 2023 Apr; 23(1):202. PubMed ID: 37118751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles.
    La Marca A; Papaleo E; Grisendi V; Argento C; Giulini S; Volpe A
    BJOG; 2012 Sep; 119(10):1171-9. PubMed ID: 22805536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance between day-3 follicle stimulating hormone & anti-Müllerian hormone is predictive of clinical pregnancy during fertility treatment.
    Butler WJ; Pico A; Hawkins KC; Younis AI
    Gynecol Endocrinol; 2021 Sep; 37(9):798-801. PubMed ID: 33355011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two different starting doses of recombinant follicle stimulating hormone (rFSH) for intrauterine insemination (IUI) cycles in non-obese women with polycystic ovary syndrome (PCOS): a retrospective cohort study.
    Seckin B; Yumusak OH; Tokmak A
    J Obstet Gynaecol; 2021 Nov; 41(8):1234-1239. PubMed ID: 33624571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-Müllerian hormone versus antral follicle count for defining the starting dose of FSH.
    Lan VT; Linh NK; Tuong HM; Wong PC; Howles CM
    Reprod Biomed Online; 2013 Oct; 27(4):390-9. PubMed ID: 23953069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of ovulation induction and intrauterine insemination in infertile patients with hypogonadotropic hypogonadism.
    Huseyin K; Berk B; Tolga K; Eser O; Ali G; Murat A
    J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):833-838. PubMed ID: 30930300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation?
    Bakas P; Boutas I; Creatsa M; Vlahos N; Gregoriou O; Creatsas G; Hassiakos D
    Gynecol Endocrinol; 2015 Oct; 31(10):765-8. PubMed ID: 26288100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into ovarian response with a fixed low dose FSH stimulation in an IUI programme: the PRORAILS study.
    Rutten A; van Ballegooijen H; Broekmans F; Cohlen B;
    Hum Reprod; 2022 Jun; 37(7):1440-1450. PubMed ID: 35460412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles.
    Allegra A; Marino A; Volpes A; Coffaro F; Scaglione P; Gullo S; La Marca A
    Reprod Biomed Online; 2017 Apr; 34(4):429-438. PubMed ID: 28189417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Müllerian hormone concentrations and antral follicle counts for the prediction of pregnancy outcomes after intrauterine insemination.
    Moro F; Tropea A; Scarinci E; Leoncini E; Boccia S; Federico A; Alesiani O; Lanzone A; Apa R
    Int J Gynaecol Obstet; 2016 Apr; 133(1):64-8. PubMed ID: 26873125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Nomogram for Individualized Gonadotropin Starting Dose in GnRH Antagonist Protocol.
    Li Y; Duan Y; Yuan X; Cai B; Xu Y; Yuan Y
    Front Endocrinol (Lausanne); 2021; 12():688654. PubMed ID: 34594300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of different starting doses of FSH on laboratory and clinical outcomes in patients with moderate AMH level.
    Liu M; Wang C; He L; Pan X; Wu C; Pu X; Pan X
    Hormones (Athens); 2024 Jun; 23(2):331-338. PubMed ID: 38342850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin releasing hormone antagonist use in controlled ovarian stimulation and intrauterine insemination cycles in women with polycystic ovary syndrome.
    Ozelci R; Dilbaz S; Dilbaz B; Cırık DA; Yılmaz S; Tekin OM
    Taiwan J Obstet Gynecol; 2019 Mar; 58(2):234-238. PubMed ID: 30910145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do younger women with elevated basal follicular stimulating hormone levels undergoing gonadotropin-stimulated intrauterine insemination cycles represent compromised reproductive outcomes?
    Devranoğlu B; Özdamar Ö; Köle E; Eken MK; Bozdağ H; Doğer E
    Eur J Obstet Gynecol Reprod Biol; 2016 Apr; 199():141-5. PubMed ID: 26930042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of pregnancy outcomes following intrauterine insemination in young women with decreased versus normal ovarian reserve.
    Tiegs AW; Sun L; Scott RT; Goodman LR
    Fertil Steril; 2020 Apr; 113(4):788-796.e4. PubMed ID: 32147173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of daily and alternate day recombinant follicle-stimulating hormone stimulation protocols for intrauterine insemination.
    Kabli N; Sylvestre C; Tulandi T; Buckett W
    Fertil Steril; 2009 Apr; 91(4):1141-4. PubMed ID: 18342857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation.
    Mitwally MF; Casper RF
    J Soc Gynecol Investig; 2004 Sep; 11(6):406-15. PubMed ID: 15350255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.